Connect with us

Hi, what are you looking for?

Jewish Business News

Business

Limaca Medical Is Working On Genetic Based Early Detection Disease testing

Limaca Medical has a new device called Precision.

Prof Iyad Khamaysi using Limaca’s KORA-GI in first-in-human trial at the advanced endoscopy unit of the gastroenterological department of RAMBAM Medical Centre, Haifa, Israel

Israeli firm Limaca Medical offers an endoscopic ultrasound-guided biopsy for precision medicine. Aptly and simply named “Precision,” the company describes its new device as the next generation endoscopic ultrasound-guided biopsy device for precision medicine.

The company states that its device is used for improved diagnosis of the gastrointestinal system and adjacent organ tumors. It uses an automated, electro-mechanical revolving needle, provides high quality core tissue samples, improved diagnostic accuracy, and enables greater patient-specific treatments.

A portfolio company of The Trendlines Group, Lima has closed $1.25 million of a $1.5 million round to complete first-in-human (“FIH”) procedures, post-market clinical studies, and obtain regulatory approvals.

You have probably heard about the recent death of beloved Jeopardy host Alex Trebek. Trebek revealed a few years ago that he was suffering from pancreatic cancer.

Pancreatic cancer is the hardest to treat and a diagnosis is usually a death sentence. The reason for this is that cancer of the pancreas is so hard to detect that by the time it is uncovered the cancer has usually spread. So the cancer is detected elsewhere in the body only after the damage to the pancreas has been done.

Pancreatic cancer has a survival rate of just 9%. Limaca’s Precision utilizes genetic profiling through the use of more advanced biopsies.

So by checking the genetics doctors can see if someone is at risk for a specific cancer and learn earlier what course of treatment to follow.

Limaca’s CEO Assaf Klein commented, “We designed Precision to improve upon endoscopic biopsies and make a substantial leap forward in this critical diagnostic procedure to advance precision treatment and achieve superior outcomes for cancer patients.”

Carl Rickenbaugh, Limaca’s Chairman, said, “The medical provider and payor markets respond to superior devices when they demonstrate strong clinical relevancy. We built Limaca to address the need for a more efficient endoscopic procedure for the provider, and for the cancer patient and payor, greater certainty to gain sufficient sample quality and quantity needed for pathology as well as more stringent genetic testing requirements.”

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Newsletter

Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

empty

The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Advertisement
cialis cialis satış